NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference, scheduled for June 17-18, 2026. President and Chief Executive Officer Dave Rosa will attend the conference in Las Vegas, NV, where he is set to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time.
The presentation, to be held in TRACK 6 - Raphael 3, will provide updates on commercialization progress and anticipated milestones for the OneRF platform, which is designed for treatment of the brain, pain management, and advanced drug delivery. Additionally, Mr. Rosa participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference, which can be viewed here.
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The Planet MicroCap Las Vegas 2026 Conference provides a platform for micro-cap companies to connect with institutional investors. For more information about the conference or to schedule a meeting with NeuroOne management, interested parties can contact their conference representative or email requests to NMTC@mzgroup.us. The webcast of the presentation will be available here, and the conference website can be accessed here.
NeuroOne's participation in this conference highlights its commitment to advancing neurological care and engaging with the investment community. The company's focus on developing innovative electrode technology and expanding its therapeutic applications underscores the potential impact on patients suffering from neurological disorders. As NeuroOne continues to progress its clinical and commercial programs, presentations like this one offer insights into its strategic direction and growth prospects.
